BioSpace News Archive

BD, a leading global medical technology company, announced the launch of a new benchtop cell analyzer that brings sophisticated flow cytometry capabilities to laboratories of all sizes.

Since many of these viruses share a multitude of strikingly similar symptoms, a single PCR test that differentiates between three primary pathogens, influenza A and B, RSV, and COVID-19, is becoming increasingly popular with physicians and patients, according to leading national laboratory GENETWORx.

Retrotope, a clinical-stage biopharmaceutical company focused on the development of novel, first-in-class therapies for degenerative diseases, announced that enrollment has been completed for its multicenter Phase 2 clinical trial evaluating RT001, the company’s lead development candidate, in patients with progressive supranuclear palsy.

Gritstone bio, Inc., a clinical-stage biotechnology company developing next generation cancer and infectious disease immunotherapies, announced that it will host a key opinion leader webinar on its neoantigen oncology programs for colorectal cancer on Wednesday, August 18, 2021 at 11am Eastern Time.

Clene Inc. along with its subsidiaries “Clene” and its wholly owned subsidiary Clene Nanomedicine, Inc., a clinical-stage biopharmaceutical company dedicated to the treatment of neurodegenerative disease using nanotechnology to treat energetic failure, announced the completion of two lease agreements that will more than quadruple the company’s manufacturing capacity for its lead asset, CNM-Au8®, a gold nanocrystal suspension.

Helius Medical Technologies, Inc. (Nasdaq:HSDT) (TSX:HSM) (“Helius” or the “Company”), a neurotech company focused on neurological wellness, today announced that the Company has launched a new website: https://ponstreatment.com, created to serve as a resource for U.S.-based patients and physicians.

Reneo Pharmaceuticals, Inc., a clinical stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare genetic, mitochondrial diseases, reported financial results for the quarter ended June 30, 2021 and provided an update on its clinical programs.

Inozyme Pharma, Inc., a rare disease biopharmaceutical company developing novel therapeutics for the treatment of abnormal mineralization, reported financial results for the second quarter ended June 30, 2021, and provided recent business highlights.

BD, a leading global medical technology company, announced that Christopher DelOrefice has been named executive vice president and chief financial officer, effective Sept. 6, 2021.

Optinose, a pharmaceutical company focused on patients treated by ear, nose and throat and allergy specialists, reported financial results for the quarter ended June 30, 2021, and provided operational updates.